ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 104 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2021. The put-call ratio across all filers is 0.42 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,937,979 | -36.1% | 612,079 | 0.0% | 0.17% | -33.5% |
| Q2 2023 | $4,596,713 | +166026.2% | 612,079 | 0.0% | 0.26% | +41.2% |
| Q1 2023 | $2,767 | -59.9% | 612,079 | 0.0% | 0.18% | -60.6% |
| Q4 2022 | $6,898 | -99.9% | 612,079 | -14.0% | 0.46% | -2.9% |
| Q3 2022 | $6,815,000 | +18.3% | 712,079 | 0.0% | 0.48% | +9.2% |
| Q2 2022 | $5,761,000 | -52.1% | 712,079 | 0.0% | 0.44% | -52.8% |
| Q1 2022 | $12,034,000 | -26.5% | 712,079 | -6.6% | 0.92% | -5.1% |
| Q4 2021 | $16,377,000 | -78.1% | 762,079 | -24.7% | 0.97% | -67.9% |
| Q3 2021 | $74,752,000 | +53.7% | 1,012,079 | +13.8% | 3.04% | +83.8% |
| Q2 2021 | $48,635,000 | -25.2% | 889,454 | +0.9% | 1.65% | +14.0% |
| Q1 2021 | $65,022,000 | -14.5% | 881,770 | 0.0% | 1.45% | -19.9% |
| Q4 2020 | $76,009,000 | +111.4% | 881,770 | -9.3% | 1.81% | +30.8% |
| Q3 2020 | $35,959,000 | – | 971,770 | – | 1.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |